Phase 2 trial targets HER2+ gastric cancer with limited treatment options

A phase 2 trial targets HER2+ gastric cancer with limited treatment options

A phase 2 trial targets HER2-positive gastric cancer patients who have limited treatment options. This research combines Evorpacept with trastuzumab, ramucirumab, and paclitaxel to assess potential survival improvements. The trial’s status remains in early testing, meaning results are not yet confirmed for clinical use. While HER2+ gastric cancer carries significant mortality risk with few established therapies, this approach offers a pathway to explore new survival outcomes. For patients facing this condition, even potential improvements in treatment access could mean better health outcomes. The source’s full details remain inaccessible, so this brief reflects only the metadata provided.

Source: Nature Medicine